FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment

The estimated 24-month DFS rate was 81% with Keytruda plus Welireg and 74% with Keytruda plus placebo. Credit: Sai Thaw Kyar / Shutterstock.com.



  • FDA MSD Keytruda Welireg